Macquarie Group’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-111
| Closed | -$8K | – | 1664 |
|
|
2025
Q2 | $8K | Sell |
111
-541
| -83% | -$36.8K | ﹤0.01% | 1627 |
|
|
2025
Q1 | $45K | Buy |
652
+549
| +533% | +$45.3K | ﹤0.01% | 1570 |
|
|
2024
Q4 | $9K | Sell |
103
-2
| -2% | -$216 | ﹤0.01% | 1586 |
|
|
2024
Q3 | $13K | Sell |
105
-71
| -40% | -$9.47K | ﹤0.01% | 1618 |
|
|
2024
Q2 | $25K | Sell |
176
-5
| -3% | -$663 | ﹤0.01% | 1624 |
|
|
2024
Q1 | $23K | Buy |
181
+3
| +2% | +$357 | ﹤0.01% | 1574 |
|
|
2023
Q4 | $18K | Buy |
178
+32
| +22% | +$3.17K | ﹤0.01% | 1610 |
|
|
2023
Q3 | $13K | Buy |
146
+90
| +161% | +$7.93K | ﹤0.01% | 1606 |
|
|
2023
Q2 | $5K | Hold |
56
| – | – | ﹤0.01% | 1645 |
|
|
2023
Q1 | $4K | Hold |
56
| – | – | ﹤0.01% | 1696 |
|
|
2022
Q4 | $4K | Sell |
56
-78
| -58% | -$4.57K | ﹤0.01% | 1733 |
|
|
2022
Q3 | $7K | Hold |
134
| – | – | ﹤0.01% | 2411 |
|
|
2022
Q2 | $7K | Sell |
134
-14
| -9% | -$777 | ﹤0.01% | 2490 |
|
|
2022
Q1 | $8 | Hold |
148
| – | – | ﹤0.01% | 2540 |
|
|
2021
Q4 | $8K | Sell |
148
-10
| -6% | -$542 | ﹤0.01% | 2537 |
|
|
2021
Q3 | $8K | Sell |
158
-50
| -24% | -$2.42K | ﹤0.01% | 2565 |
|
|
2021
Q2 | $9K | Hold |
208
| – | – | ﹤0.01% | 2481 |
|
|
2021
Q1 | $7K | Hold |
208
| – | – | ﹤0.01% | 2430 |
|
|
2020
Q4 | $7K | Sell |
208
-34
| -14% | -$1.18K | ﹤0.01% | 2335 |
|
|
2020
Q3 | $8K | Sell |
242
-36
| -13% | -$1.2K | ﹤0.01% | 2303 |
|
|
2020
Q2 | $9K | Hold |
278
| – | – | ﹤0.01% | 2301 |
|
|
2020
Q1 | $8K | Hold |
278
| – | – | ﹤0.01% | 1942 |
|
|
2019
Q4 | $8K | Hold |
278
| – | – | ﹤0.01% | 1887 |
|
|
2019
Q3 | $7K | Buy |
278
+36
| +15% | +$910 | ﹤0.01% | 1859 |
|
|
2019
Q2 | $6K | Buy |
+242
| New | +$5.98K | ﹤0.01% | 1809 |
|
|
2016
Q4 | – | Sell |
-4,351,744
| Closed | -$90.5M | – | 1565 |
|
|
2016
Q3 | $90.5M | Sell |
4,351,744
-6,443,284
| -60% | -$160M | 0.17% | 95 |
|
|
2016
Q2 | $290M | Buy |
10,795,028
+3,460,788
| +47% | +$94.9M | 0.28% | 64 |
|
|
2016
Q1 | $199M | Sell |
7,334,240
-374,952
| -5% | -$10M | 0.4% | 53 |
|
|
2015
Q4 | $224M | Sell |
7,709,192
-136,802
| -2% | -$3.79M | 0.46% | 54 |
|
|
2015
Q3 | $213M | Sell |
7,845,994
-107,956
| -1% | -$3.06M | 0.46% | 55 |
|
|
2015
Q2 | $218M | Sell |
7,953,950
-63,748
| -0.8% | -$1.79M | 0.43% | 56 |
|
|
2015
Q1 | $214M | Buy |
8,017,698
+713,060
| +10% | +$16.4M | 0.42% | 55 |
|
|
2014
Q4 | $155M | Sell |
7,304,638
-64,968
| -0.9% | -$1.45M | 0.32% | 67 |
|
|
2014
Q3 | $175M | Sell |
7,369,606
-96,258
| -1% | -$2.22M | 0.38% | 64 |
|
|
2014
Q2 | $172M | Sell |
7,465,864
-16,265,466
| -69% | -$359M | 0.38% | 63 |
|
|
2014
Q1 | $542M | Buy |
23,731,330
+701,930
| +3% | +$15M | 0.94% | 18 |
|
|
2013
Q4 | $425M | Sell |
23,029,400
-124,740
| -0.5% | -$2.17M | 0.76% | 30 |
|
|
2013
Q3 | $392M | Sell |
23,154,140
-1,031,850
| -4% | -$17.4M | 0.77% | 25 |
|
|
2013
Q2 | $375M | Buy |
+24,185,990
| New | +$403M | 0.82% | 23 |
|
Other funds holding NVO
F
Macquarie Group's NVO Position: Q3 2025 in Review
Macquarie Group sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 111 shares — an estimated $8K sold.
Macquarie Group first reported a position in NVO in Q2 2013 and held it in 39 quarters. The position peaked at $542M in Q1 2014. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.
- Macquarie Group reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
- Macquarie Group sold 111 Novo Nordisk shares in Q3 2025, an estimated $8K.
- Macquarie Group first reported a position in Novo Nordisk in Q2 2013 and held it in 39 quarters.
- Macquarie Group's Novo Nordisk position peaked at $542M in Q1 2014.
- 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.
Based on Macquarie Group's 13F filing for Q3 2025, filed 13 Nov 2025.